Oncology pathways have been a hot topic of discussion for several years. Perceptions, even definitions, of pathways are highly variable, and their true impact on oncologists’ treatment selection is nuanced. This week, Market Access Insights published the first of two deliverables for our inaugural pathway report, and we want to share a few topline findings!
Welcome to the April 2024 edition of our Monthly Insight Series. This month we’re looking at community oncology practices’ reliance on buy-and-bill drug revenues.
Lee BlansettNavigating IDNs requires understanding their financial drivers, revenue streams, and cost management. Here, we look at IDNs' key financial aspects, such as revenue optimization strategies, and examine the potential effects of site-neutral payment reforms.
Emma BijesseWelcome to the March 2024 edition of our Monthly Insight Series. This month we examine the trend of oncologists consolidating into IDNs and network aggregators.
Taylor Crutison